Short interest for Adicet Bio gives investors a sense of the degree to which investors are betting on the decline of Adicet Bio's stock. Short interest data is updated every two weeks.

Adicet Bio Stock (NASDAQ:ACET), Short Interest Report

Adicet Bio

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

IN8bio’s Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data 

Biotech

Penny Stocks

General

ACET

INAB

IPSC

IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these cells to effectively target and eliminate cancer cells in both solid and hematological tumors.

IN8bio&#39;s Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data

News

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACCD

ACMR

AIMD

BETS

BOWL

CENX

CUTR

DECA

GOEV

GRFS

GRTX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

ILMN

JBLU

JNPR

JWEL

KITT

KORE

LDTC

Morgan Stanley Capital Protected Notes for S&P 500 Index

NEOG

NEXI

SNTG

TCJH

TLRY

URBN

VIRI

YCBD

ZCAR

PTHR

Shares of JetBlue Airways Corporation (NASDAQ: JBLU) fell sharply during Tuesday’s session.

Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

BZ_Stock_Whisper_Index_Logo_6

Exclusives

$BTC

MARA

MOBX

OMGA

SIDU

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.

Benzinga&#39;s &#39;Stock Whisper&#39; Index: 5 Stocks Investors Secretly Monitor But Don&#39;t Talk About Yet

Adicet Bio Inc

Wedbush analyst Robert Driscoll reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Outperform and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

Wedbush Reiterates Outperform on Adicet Bio, Maintains $5 Price Target

Adicet Today Presented Abstract Featuring Preclinical Data Highlighting ADI-270 At ASGCT27th Annual Meeting

HC Wainwright &amp; Co. analyst Edward White maintains Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and maintains $10 price target.

HC Wainwright & Co. Maintains Buy on Adicet Bio, Maintains $10 Price Target

Offerings

Adicet Bio May Offer And Sell Shares Of Common Stock Having An Aggregate Offering Price Of Up To $100M From Time To Time

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and maintains $10 price target.

HC Wainwright & Co. Reiterates Buy on Adicet Bio, Maintains $10 Price Target

Canaccord Genuity analyst John Newman reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and maintains $19 price target.

Canaccord Genuity Reiterates Buy on Adicet Bio, Maintains $19 Price Target

Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) reported its Q4 earnings results on Tuesday, March 19, 2024 at 04:10 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Adicet Bio missed estimated earnings by 0.0%, reporting an EPS of $-0.69 versus an estimate of $-0.69.
Revenue was down $0 from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.03 which was followed by a 6.0% drop in the share price the next day.

To track all earnings releases for Adicet Bio <a href="https://www.benzinga.com/quote/ACET/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Adicet Bio: Q4 Earnings Insights

Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.70) by 1.43 percent.

Earnings Beats

Adicet Bio Q4 2023 GAAP EPS $(0.69) Beats $(0.70) Estimate

HC Wainwright &amp; Co. analyst Edward White maintains Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and lowers the price target from $26 to $10.

HC Wainwright & Co. Maintains Buy on Adicet Bio, Lowers Price Target to $10

The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately&nbsp;$85.2 million, excluding any exercise of the underwriters&#39; option to purchase additional shares. All of the securities in the offering are to be sold by Adicet. The offering is expected to close on or about January 25, 2024, subject to customary closing conditions.

Adicet Bio Prices Public Offering Of 27,054,667 Common Shares At $2.40/share, And Pre-Funded Warrants To Purchase 8,445,333 Common Shares At $2.3999/Pre-Funded Warrant

<h3>Gainers</h3>
<ul>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares moved upwards by 8.5% to $1.15 during Monday's after-market session. The market value of their outstanding shares is at $14.9 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares moved upwards by 6.98% to $9.95. The company's market cap stands at $20.2 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock increased by 6.94% to $0.97. The market value of their outstanding shares is at $53.1 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares moved upwards by 6.08% to $2.44. The market value of their outstanding shares is at $1.6 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock increased by 5.76% to $0.31. The market value of their outstanding shares is at $15.1 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock rose 5.62% to $0.37. The market value of their outstanding shares is at $9.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) shares decreased by 22.1% to $1.94 during Monday's after-market session. The company's market cap stands at $83.7 million. </li>
<li>Adagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>) stock fell 13.34% to $2.6. The company's market cap stands at $113.9 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares declined by 6.9% to $3.51. The company's market cap stands at $1.8 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares fell 5.96% to $0.79. </li>
<li>Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) shares declined by 5.87% to $19.27. The company's market cap stands at $825.7 million. </li>
<li>DocGo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCGO#NASDAQ">DCGO</a>) shares fell 5.49% to $3.25. The company's market cap stands at $337.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAG

BBLG

BCLI

CABA

CVKD

DCGO

KZIA

PASG

RNAZ

TCBP

VTVT

12 Health Care Stocks Moving In Monday's After-Market Session

Adicet Bio, Inc. Announces Proposed Public Offering

IN8bio (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inab#NASDAQ">INAB</a>) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these cells to effectively target and eliminate cancer cells in both solid and hematological tumors. IN8bio&#39;s pipeline consists of a range of preclinical and clinical investigational therapies that aim to address various types of cancer with large unmet needs.&nbsp;
Leukemia, with a specific focus on Acute Myeloid Leukemia (AML) and potentially Myelodysplastic Syndrome (MDS), is an area of interest for IN8bio. The AML market is projected to to grow from <a href="https://www.bccresearch.com/market-research/pharmaceuticals/acute-myeloid-leukemia-market.html#:~:text=The%20global%20acute%20myeloid%20leukemia%20market%20is%20projected%20to%20grow,10.0%25%20during%20the%20forecast%20period.">$3.5 billion in 2022</a> to $6.1 billion in 2028 &ndash; representing a CAGR of 10%, while the MDS market which was worth <a href="https://www.coherentmarketinsights.com/market-insight/myelodysplastic-syndrome-treatment-market-775">$ 3.3 billion in 2022</a> is expected to exhibit a CAGR of 9.3% over 2023-2030. IN8bio&#39;s INB-100 is an allogeneic-derived, gamma-delta T-cell product candidate aimed at addressing the unmet need in these areas.
<a href="https://investors.in8bio.com/news-releases/news-release-details/in8bio-announces-positive-clinical-update-demonstrating">The latest clinical data from the INB-100</a> trial presented in December 2023 at the 65th American Society of Hematology (ASH) Annual Meeting shows that patients who received this treatment experienced a significant increase and persistence of allogeneic gamma-delta T cells in the first year following treatment. Previously published data demonstrate that leukemia patients with high levels of gamma-delta T cells have better survival outcomes. Compared with patients who underwent haploidentical hematopoietic stem cell transplantation (HSCT) without INB-100 therapy, those who received INB-100 at Dose Level (DL) 2 had gamma-delta T cell levels that were, on average, 49 times higher at 60 days. Additionally, the levels were 8 times higher than those achieved at DL 1, showing a dose-response relationship. At 365 days, the levels were 2.7 times higher than those in DL 1, which is considered beneficial for survival outcomes.
&ldquo;With more patients and a longer observation period, we are excited to report that 100% of evaluable dosed patients continue to remain in morphological complete remission, with six patients remaining alive and relapse-free beyond one year,&rdquo; <a href="https://investors.in8bio.com/news-releases/news-release-details/in8bio-announces-positive-clinical-update-demonstrating">shared Trishna Goswami</a>, MD, Chief Medical Officer at IN8bio. &ldquo;Leukemic relapse is the leading cause of death in patients undergoing HSCT and prevention of relapse remains a high unmet need. In this trial, the first three patients were high-risk or relapsed AML patients with complex cytogenetics. We are happy to report two of the patients remain alive and relapse-free for over three years, and the third is now past two years. Furthermore, INB-100 has demonstrated for the first time, the in-vivo expansion and persistence of an allogeneic, or donor-derived, cellular therapy at 365 days with blood levels of gamma-delta T cells surpassing levels previously observed to be associated with greater survival.&rdquo;
Other positive observations include increases in CD4+, CD8+ T cells, NK cells and B cells, indicating a favorable response and stable immune system reconstruction after the transplant. Cytokine data also showed increased pro-inflammatory cytokines in the blood shortly after gamma-delta T cell infusion, demonstrating overall immune activation.
Updated safety data through November 3, 2023, includes three more patients. 60% of the treated patients experienced low-grade acute graft versus host disease (GvHD), but all cases responded well to steroid treatment. Three patients experienced chronic GvHD and no dose-limiting toxicities were observed. Across DL 1 and DL 2, all patients in the study remained alive and in complete remission, with two patients now remaining progression-free for more than three years.&nbsp;
While there are other companies, such as Adicet Bio (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acet#NASDAQ">ACET</a>) and Century Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipsc#NASDAQ">IPSC</a>), that are also studying gamma-delta T cells, IN8bio&#39;s DeltEx platform and clinical results set the company apart from competitors in the field of cancer therapy. The company seems to have a focused vision for the path forward, and it recently announced that it has entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to $46.9 million at increasing valuations. The deal includes initial gross proceeds of $14.4 million and extends the company&rsquo;s runway into 2025.&nbsp;
IN8bio&rsquo;s expertise, proprietary techniques and scalable manufacturing process potentially position it as a leader in harnessing the potential of gamma-delta T cells for the development of innovative and effective cancer treatments, and the company may be one to watch for those interested in this growing market.
Featured photo by<a href="https://unsplash.com/@nci?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash"> National Cancer Institute</a> on<a href="https://unsplash.com/photos/red-round-fruits-on-white-and-blue-surface-mbL91Lg56zc?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash"> Unsplash</a>.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data

Shares of JetBlue Airways Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jblu#NASDAQ">JBLU</a>) fell sharply during Tuesday&rsquo;s session.
JetBlue&rsquo;s President &amp; COO Joanna Geraghty will succeed Robin Hayes as CEO, effective Feb. 12, 2024. B of A Securities analyst Andrew Didora downgrades JetBlue Airways from Neutral to Underperform and lowered the price target from $6 to $3.
JetBlue Airways shares dipped 10.9% to $5.13 on Tuesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) shares jumped 89.2% to $14.32.</li>
<li>Sentage Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sntg#NASDAQ">SNTG</a>) shares climbed 65.3% to $3.52.</li>
<li>MicroCloud Hologram Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holo#NASDAQ">HOLO</a>) gained 41.9% to $0.3450.</li>
<li>Cutera, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cutr#NASDAQ">CUTR</a>) surged 28.2% to $4.2150. Cutera said it expects FY23 revenue of $211.5 million to $212.5 million versus prior guidance of $205 million.</li>
<li>Virios Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/viri#NASDAQ">VIRI</a>) shares rose 28% to $0.7520.</li>
<li>Galera Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grtx#NASDAQ">GRTX</a>) jumped 26% to $0.1880.</li>
<li>Adicet Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acet#NASDAQ">ACET</a>) gained 26% to $3.10.</li>
<li>NGM Biopharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ngm#NASDAQ">NGM</a>) gained 24.6% to $1.5700. NGM Bio announced clinical data from trial of NGM707 In advanced solid tumors and outlines evolved strategy for aldafermin and NGM120.</li>
<li>Galera Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grtx#NASDAQ">GRTX</a>) gained 23.5% to $0.1844.</li>
<li>Juniper Networks, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnpr#NYSE">JNPR</a>) rose 21.5% to $36.71. Hewlett Packard Enterprise Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hpe#NYSE">HPE</a>) is reportedly in advanced discussions to acquire networking equipment competitor Juniper Networks.</li>
<li>LeddarTech Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ldtc#NASDAQ">LDTC</a>) gained 19.1% to $3.99. LeddarTech launched LeddarVision Surround-View (LVS-2+), a premium highway assist software stack on an embedded platform, at CES 2024.</li>
<li>cbdMD, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ycbd#NYSE">YCBD</a>) rose 18.7% to $0.8680.</li>
<li>Accolade, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/accd#NASDAQ">ACCD</a>) climbed 17.2% to $13.61 following third-quarter results.</li>
<li>Century Aluminum Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cenx#NASDAQ">CENX</a>) jumped 14.4% to $12.18. B. Riley Securities upgraded Century Aluminum from Neutral to Buy and raised the price target from $10 to $14.</li>
<li>ACM Research, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acmr#NASDAQ">ACMR</a>) gained 12.8% to $19.22. ACM Research said it sees FY23 revenue of $530 million to $545 million.</li>
<li>Jowell Global Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jwel#NASDAQ">JWEL</a>) gained 10.8% to $2.25.</li>
<li>Acuity Brands, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ayi#NYSE">AYI</a>) jumped 10.2% to $225.51 after the company reported better-than-expected first-quarter earnings.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zcar#NASDAQ">ZCAR</a>) rose 10.1% to $4.37.</li>
<li>Urban Outfitters, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/urbn#NASDAQ">URBN</a>) gained 9.1% to $39.17 after the company reported a 10% increase in total company net sales for the two months ended Dec. 31, 2023.</li>
<li>Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>) rose 8.2% to $144.72 after the company reported preliminary FY23 consolidated revenue guidance above estimates.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Denali Capital Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/deca#NASDAQ">DECA</a>) shares fell 28.6% to $7.80.</li>
<li>Top KingWin Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcjh#NASDAQ">TCJH</a>) fell 26% to $0.8660 after dipping 39% on Monday.</li>
<li>Grifols, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NASDAQ">GRFS</a>) shares fell 24.6% to $8.39 following a report from Gotham City Research titled &quot;Grifols SA: Scranton and the Undisclosed Debts.&quot;</li>
<li>Pono Capital Three, Inc. (NASDAQ: PTHR) declined 22.4% to $7.64.</li>
<li>Nauticus Robotics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kitt#NASDAQ">KITT</a>) dipped 20.6% to $0.2920.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ejh#NASDAQ">EJH</a>) fell 17.5% to $0.4291.</li>
<li>Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) dipped 16.8% to $1.53. Safe and Green Development announced strategic property monetization initiative throughout 2024.</li>
<li>Ainos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aimd#NASDAQ">AIMD</a>) fell 16% to $2.42.</li>
<li>The Container Store Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tcs#NYSE">TCS</a>) dipped 15.2% to $1.9599. The Container Store Group said it sees third-quarter net sales of $214 million versus estimates of $225.38 million.</li>
<li>Canoo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goev#NASDAQ">GOEV</a>) shares fell 14.1% to $0.2163. Canoo shares gained around 6% on Monday after the company announced the purchase of manufacturing assets &quot;at dramatically reduced prices&quot; to scale production at its Oklahoma City facility.</li>
<li>KORE Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kore#NYSE">KORE</a>) dipped 10.7% to $0.9099.</li>
<li>Bit Brother Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bets#NASDAQ">BETS</a>) fell 10.7% to $0.0058 after dipping 15% on Monday. Bit Brother announced a 1-for-1,000 reverse share split.</li>
<li>Tilray Brands, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>) fell 9.6% to $2.1150 following weak quarterly sales.</li>
<li>MorphoSys AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mor#NASDAQ">MOR</a>) dipped 9.1% to $9.18.</li>
<li>Neogen Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/neog#NASDAQ">NEOG</a>) fell 8.6% to $18.14 after the company reported worse-than-expected second-quarter financial results and lowered its FY24 sales guidance below estimates.</li>
<li>Unity Software Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/u#NYSE">U</a>) fell 8% to $35.85 after it disclosed a job cut.</li>
<li>Bowlero Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bowl#NYSE">BOWL</a>) declined 7.6% to $12.62.</li>
<li>Hewlett Packard Enterprise Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hpe#NYSE">HPE</a>) fell 7.5% to $16.42. HP might be on the verge of acquiring Juniper Networks, in a deal possibly worth around $13 billion. The announcement could be made as early as this week, according to The Wall Street Journal.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36550880/i-think-you-have-a-winner-and-it-is-just-on-fire-jim-cramer-on-this-brazilian-stock"> &#39;I Think You Have A Winner, And It Is Just On Fire&#39;: Jim Cramer On This Brazilian Stock</a>

Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>NexImmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXI#NASDAQ">NEXI</a>) shares rose 97.5% to $14.95 during Tuesday's regular session. The company's market cap stands at $15.8 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) stock moved upwards by 36.47% to $4.49. The company's market cap stands at $89.8 million. </li>
<li>Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) stock rose 32.72% to $3.27. The company's market cap stands at $140.9 million. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) stock rose 30.42% to $7.76. The company's market cap stands at $156.5 million. </li>
<li>Galera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) stock increased by 25.4% to $0.19. The market value of their outstanding shares is at $10.1 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock increased by 22.47% to $0.9. The company's market cap stands at $2.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined by 23.7% to $8.49 during Tuesday's regular session. The company's market cap stands at $5.7 billion. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares decreased by 13.6% to $0.24. The company's market cap stands at $14.3 million. </li>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) shares decreased by 13.55% to $2.49. The company's market cap stands at $11.6 million. </li>
<li>PHAXIAM Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHXM#NASDAQ">PHXM</a>) stock decreased by 13.38% to $4.6. The market value of their outstanding shares is at $27.9 million. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) stock fell 11.7% to $1.89. The market value of their outstanding shares is at $40.1 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares decreased by 11.56% to $0.35. The company's market cap stands at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GNPX

MODD

PHXM

SLDB

STSS

12 Health Care Stocks Moving In Tuesday's Intraday Session

Each week,&nbsp;Benzinga&#8217;s Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and warrant attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance to&nbsp;uncover new information.
This index layers editorial commentary to help make sense of why these stocks should be of interest and whether investors or casual readers should watch them.
Here is a look at the Benzinga Stock Whisper Index for the week of Jan. 5:
Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>): The biotechnology company saw shares surge this week after <a href="https://www.benzinga.com/general/biotech/24/01/36488184/famed-obesity-drug-maker-novo-nordisk-inks-collaborations-for-cardiometabolic-diseases">announcing a collaboration</a> with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) for cardiometabolic diseases. Under the terms of the collaboration, Novo Nordisk will leverage the platform technology to help with new treatments for obesity management. The deal is worth up to $532 million including upfront payments, development costs, milestone payments and tiered royalties.
Marathon Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>): Stocks related to Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continue to see strong interest from readers as the approval of Bitcoin ETFs by the SEC remains a possibility in the month of July. Marathon Digital <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36489079/bitcoin-miner-marathon-digital-is-moving-higher-thursday-whats-going-on">announced an update</a> on its Bitcoin mining during the week, which led to an increase in the share price. Marathon hit a record Bitcoin production of 1,853 BTC in December and 12,852 BTC for 2023. At the time of the report, Marathon owns over 15,000 Bitcoin.
Related Link:<a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36481618/bitcoin-etf-could-be-just-days-away-are-you-ready"> Bitcoin ETF Could Be Just Days Away — Are You Ready?</a>
Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>): The semiconductor company saw shares trade higher after announcing a 15-month contract award as part of the U.S. Army's M-1 Abrams Tank program. The company will provide electromagnetic interference filtered connectors to an unnamed Honeywell subcontractor until June 2025. The financial terms of the deal were not disclosed.
"This is a key design win and validation of our successful acquisition of EMI Solutions as we continue to gain further access into the large and important military vertical," Mobix Labs CEO Fabian Battaglia said.
Mobix Labs recently completed a SPAC merger to go public in December.
Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>): The clinical-stage biotechnology company saw shares trade higher after providing an <a href="https://investor.adicetbio.com/news-releases/news-release-details/adicet-provides-corporate-update-and-highlights-strategic">update </a>on the outlook for 2024. Goals include expanding clinical development of ADI-001 into autoimmune diseases. A clinical update on ADI-001 Phase 1 trial for mantle cell lymphoma is expected in the second half of 2024. 
The company also said it expects ADI-270 to have an investigational new drug submission for renal cell carcinoma in the second quarter of 2024. Adicet Bio said its cash on hand is expected to fund current and planned operations into the second half of 2025.
"In 2024, we aim to make significant strides across our pipeline of differentiated gamma delta T cell therapies through our strategic and disciplined approach," Adicent Bio CEO Chen Schor said.
Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>): The space and defense-as-a-service stock makes a second straight appearance on the Stock Whisper Index. Shares of the company traded higher after Sidus Space <a href="https://www.benzinga.com/markets/equities/24/01/36470201/why-space-and-data-as-a-service-company-sidus-space-shares-are-skyrocketing-today">said it was </a>granted a Tier 1 remote sensing license to include Panchromatic (PAN) and Shortwave Infrared (SWIR) imaging capabilities by the National Oceanic and Atmospheric Administration (NOAA).
The approval includes the upcoming LizzieSat launch set for March 2024 and future LizzieSat satellite launches. Sidus will be able to provide data on various aspects such as trends in marine traffic, activities related to illegal fishing, crop production metrics, and locations of methane emissions.
Stay tuned for next week&#8217;s report, and follow Benzinga Pro for all the latest headlines and<a href="https://pro.benzinga.com/feature/newsfeed/?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=tdEE0VrK8Jeg&amp;ref=lukejacobi5348" target="_blank" rel="noreferrer noopener">&nbsp;top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<a href="https://www.benzinga.com/exclusives/23/12/36050179/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">Dec. 1</a>
<a href="https://www.benzinga.com/top-stories/23/12/36157420/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">Dec. 8</a>
<a href="https://www.benzinga.com/top-stories/23/12/36261090/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">Dec. 15</a>
<a href="https://www.benzinga.com/markets/cryptocurrency/23/12/36367046/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">Dec. 22</a>
<a href="https://www.benzinga.com/general/biotech/23/12/36429626/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">Dec. 29</a>
Now Read: <a href="https://www.benzinga.com/markets/equities/24/01/36510120/short-sellers-nightmare-195b-evaporates-in-2023s-market-surge">Short Sellers&#8217; Nightmare: $195B Evaporates In 2023&#8217;s Market Surge</a>
Image: Benzinga

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Shares of Mobileye Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mbly#NASDAQ">MBLY</a>) fell sharply during Thursday&rsquo;s session after the company issued preliminary FY23 financial <a href="https://www.benzinga.com/news/earnings/24/01/36490653/why-system-software-company-mobileye-shares-are-diving-today">results and initial 2024 guidance</a>.
For the fourth quarter, the company expects revenue of $634 million-$638 million (vs. $636.39 million) and adjusted operating income of $241 million-$247 million. The company&#39;s previous implied guidance was $623 million-$648 million in revenue.
Wolfe Research analyst Shreyas Patil downgraded Mobileye Global from Outperform to Peer Perform.
Mobileye Global shares dipped 23.5% to $30.37 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Minim, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) shares jumped 170.2% to $4.62.</li>
<li>Omega Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omga#NASDAQ">OMGA</a>) gained 92.7% to $5.26 after Novo Nordisk entered into a research collaboration with the company.</li>
<li>Avenue Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atxi#NASDAQ">ATXI</a>) shares climbed 65.8% to $0.2920 after the company announced it reached a final agreement with the FDA for the Phase 3 safety study for IV tramadol.</li>
<li>Jeffs&#39; Brands Ltd(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfbr#NASDAQ">JFBR</a>) gained 40% to $4.41 after surging 25% on Wednesday. Jeffs&#39; Brands, last month, signed non-binding letters of intent with Sky Growth Partners to invest in a DLP laser-based system for counter-drone solutions and laser-based wireless charging technology.</li>
<li>Mobix Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mobx#NASDAQ">MOBX</a>) gained 33.3% to $4.00. Mobix Labs was awarded 15-month contract to supply EMI filtered connectors as part of US Army&#39;s M-1 Abrams Tank Program.</li>
<li>ATIF Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atif#NASDAQ">ATIF</a>) jumped 30.6% to $1.32.</li>
<li>Adicet Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acet#NASDAQ">ACET</a>) surged 26.1% to $2.22. Adicet Bio issued corporate updates and highlighted upcoming priorities for its pipeline programs in 2024.</li>
<li>Smart for Life, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smfl#NASDAQ">SMFL</a>) gained 22.6% to $1.9999.</li>
<li>XORTX Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xrtx#NASDAQ">XRTX</a>) rose 21.7% to $2.97. Alliance Global Partners analyst James Molloy maintained XORTX Therapeutics with a Buy and raised the price target from $9 to $14.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) climbed 20.1% to $0.1690 after falling over 11% on Wednesday. Kintara Therapeutics, last month, announced a review of strategic alternatives focused on maximizing stockholder value.</li>
<li>QuantumScape Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/qs#NYSE">QS</a>) gained 18.5% to $7.70.</li>
<li>The Arena Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aren#NYSE">AREN</a>) shares rose 16.8% to $2.44 after falling over 9% on Wednesday. Arena Group Board, last month, terminated employment of CEO Ross Levinsohn.</li>
<li>NuZee, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nuze#NASDAQ">NUZE</a>) gained 16.7% to $2.9999.</li>
<li>Keros Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kros#NASDAQ">KROS</a>) gained 15.7% to $47.72. Keros Therapeutics priced upsized $140 million public offering of 3.5 million common shares at $40 per share.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dyn#NASDAQ">DYN</a>) gained 14.6% to $16.92. Dyne Therapeutics announced an underwritten public offering of $175 million of common stock.</li>
<li>TMC the metals company Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmc#NASDAQ">TMC</a>) rose 13.8% to $1.32.</li>
<li>MINISO Group Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mnso#NYSE">MNSO</a>) gained 9.7% to $21.87.</li>
<li>Nikola Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkla#NASDAQ">NKLA</a>) rose 8.4% to $0.8031. Nikola said it produced 42 and wholesaled 35 Class 8 Nikola Hydrogen Fuel Cell Vehicles for US and Canada customers in 2023.</li>
<li>Select Medical Holdings Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sem#NYSE">SEM</a>) gained 6.4% to $25.00. Select Medical announced potential separation of Concentra.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>SELLAS Life Sciences Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sls#NASDAQ">SLS</a>) shares fell 36% to $0.58 after the company announced pricing of $9.0 million public offering.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ejh#NASDAQ">EJH</a>) fell 33.2% to $0.9894.</li>
<li>OPKO Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opk#NASDAQ">OPK</a>) shares dipped 28% to $1.0799. OPKO Health disclosed a private offering of Convertible Senior Notes due 2029.</li>
<li>Hitek Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hkit#NASDAQ">HKIT</a>) tumbled 25.2% to $0.77.</li>
<li>Relmada Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rlmd#NASDAQ">RLMD</a>) declined 24% to $3.44 after the company issued a corporate update.</li>
<li>Nemaura Medical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmrd#NASDAQ">NMRD</a>) dipped 21.2% to $0.1009.</li>
<li>ABVC BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abvc#NASDAQ">ABVC</a>) shares fell 20.1% to $1.5395. ABVC BioPharma shares jumped over 60% on Wednesday after the company and its subsidiary received a milestone payment of 46 million shares from AiBtl BioPharma under a global licensing payment.</li>
<li>LifeMD, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lfmd#NASDAQ">LFMD</a>) fell 20.1% to $6.20.</li>
<li>Singularity Future Technology Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgly#NASDAQ">SGLY</a>) tumbled 18.3% to $0.47.</li>
<li>cbdMD, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ycbd#NYSE">YCBD</a>) dipped 16.1% to $0.8302.</li>
<li>RiskOn International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roi#NASDAQ">ROI</a>) shares fell 13.7% to $0.2536 after dipping around 35% on Wednesday.</li>
<li>WW International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ww#NASDAQ">WW</a>) tumbled 13.6% to $6.59.</li>
<li>Pinstripes Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pnst#NYSE">PNST</a>) declined 13.1% to $7.13.</li>
<li>Avanos Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avns#NASDAQ">AVNS</a>) fell 12.9% to $18.91 after reporting preliminary Q4 and FY23 financial results.</li>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) fell 11.5% to $5.49 after jumping around 153% on Wednesday.</li>
<li>Schnitzer Steel Industries, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdus#NASDAQ">RDUS</a>) declined 9.8% to $26.61 following first-quarter results.</li>
<li>Evotec SE (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evo#NASDAQ">EVO</a>) shares declined 9.2% to $9.60. Evotec and Owkin announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation.</li>
<li>Walgreens Boots Alliance, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wba#NASDAQ">WBA</a>) dipped 8.5% to $23.39 following quarterly results.</li>
<li>MultiPlan Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mpln#NYSE">MPLN</a>) fell 7.3% to $1.3150. MultiPlan named Travis Dalton as President and CEO on March 1, 2024.</li>
<li>First Wave BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fwbi#NASDAQ">FWBI</a>) shares fell 7.1% to $5.07. First Wave BioPharma shares jumped 43% on Wednesday after Roth MKM maintained a Buy rating on the stock and adjusted its target from $11 to $40.</li>
<li>Altice USA, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/atus#NYSE">ATUS</a>) fell 4.8% to $2.9310.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36490884/bitcoin-rises-above-43-000-following-adp-data-beam-emerges-as-top-gainer"> Bitcoin Rises Above $43,000 Following ADP Data; Beam Emerges As Top Gainer</a>

ABVC

AREN

ATIF

ATUS

ATXI

AVNS

FWBI

HKIT

JFBR

KROS

Kintara Therapeutics, Inc. - Common Stock

KTRA

LFMD

MBLY

MINM

MNSO

MPLN

NKLA

NMRD

NUZE

PNST

RDUS

RLMD

SGLY

SMFL

XRTX

Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) shares increased by 99.6% to $5.45 during Thursday's regular session. The market value of their outstanding shares is at $300.5 million. </li>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares increased by 56.08% to $0.27. The company's market cap stands at $3.6 million. </li>
<li>Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) stock rose 30.28% to $19.24. The market value of their outstanding shares is at $1.1 billion. </li>
<li>Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) shares moved upwards by 25.0% to $2.2. The company's market cap stands at $94.9 million. </li>
<li>Bright Health Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHG#NYSE">BHG</a>) stock increased by 24.15% to $11.36. The company's market cap stands at $90.6 million. </li>
<li>Werewolf Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>) shares moved upwards by 20.22% to $5.23. The market value of their outstanding shares is at $189.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SELLAS Life Sciences Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLS#NASDAQ">SLS</a>) stock decreased by 35.7% to $0.58 during Thursday's regular session. The company's market cap stands at $18.6 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock declined by 30.69% to $3.14. The market value of their outstanding shares is at $94.5 million. </li>
<li>LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) shares declined by 29.99% to $5.44. The company's market cap stands at $213.2 million. </li>
<li>OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) stock declined by 28.13% to $1.08. The company's market cap stands at $833.4 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) stock declined by 25.83% to $149.09. The company's market cap stands at $1.1 billion. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) stock fell 20.37% to $1.54. The company's market cap stands at $11.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HOWL

ZJYL

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

Adicet Bio shares are trading higher after the company announced its 2024 goals to advance allogeneic T cell therapy candidates to address needs for oncology and autoimmune diseases.

Canaccord Genuity analyst John Newman maintained a Buy rating on Adicet Bio (ACET – Research Report) yesterday and set a price target of $19.00. Jo...

Adicet Bio's Promising Drug Pipeline and Buy Rating Justification

Adicet Bio Inc (ACET) said after close Tuesday that it lost $0.69 per share in quarter four 2023. On the revenue line, the company reported $0.00, missing estimates by $620 thousand.In the same quarter a year ago, the company lost $0.72 per share on revenue of $0.00. The stock is up 1.72% to $2.07 after the report.The firm

Adicet Bio Inc Up 1.72% To $2.07 After Earnings Meet

Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Adicet Bio (ACET – Research Report). The associated price target is $6.00. S...

Buy Rating Affirmed for Adicet Bio Amid Promising CAR T-Cell Therapies and Strong Financial Footing

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Adicet Bio (ACET – Research Report). The associated price target is $10...

Adicet Bio: A Strong Buy on Robust Financials and Promising Clinical Trials

Adicet Bio (ACET – Research Report) received a Buy rating and price target from Truist Financial analyst Asthika Goonewardene today. The company's ...

Adicet Bio (ACET) Receives a New Rating from Truist Financial

BGFV, STI and HNST are among after hour movers

Adicet Bio Inc (ACET) stock is higher by 10.00% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator. Adicet Bio Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ACET!See Full ACET ReportWhat is Stock Sentiment?Sentiment uses short

Should You Buy Adicet Bio Inc (ACET) Stock After it Has Risen 10.00% in a Week?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
In most cases, investors should stay away from <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>. They&rsquo;re wild, they&rsquo;re unpredictable and they tend to lose their stakeholders money more so than they return. It&rsquo;s just not a good place to consistently bolster your portfolio.



That said, the allure of penny stocks is understandable. Basically, they benefit from the law of small numbers. It doesn&rsquo;t take much &ldquo;energy&rdquo; to move a small object up a ladder as compared to a heavy, bulky item. In similar fashion, if the stars align just right, these speculative vehicles could rocket higher.



Adding to that temptation, there are a select few market wagers that also carry analyst consensus buy ratings. This doesn&rsquo;t guarantee anything, let me be crystal clear. However, if you&rsquo;re going to gamble on penny stocks, you might as well do so the smart way.



<h2>Arbe Robotics (ARBE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/penny-1600-300x169.jpg" alt="Pennies in a jar on top of a background of blurred pennies. Penny stocks."><div>Source: John Brueske / Shutterstock</div></div>A semiconductor company, Arbe Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/arbe-stock-quote/">ARBE</a>) provides 4D imaging radar solutions for tier 1 automotive suppliers and automotive manufacturers in China, Sweden, Germany, Switzerland, the U.S., Italy and Israel. It offers 4D imaging radar chipset solutions that address the core issues that have caused autonomous vehicle and autopilot accidents, such as detecting stationary objects, identifying vulnerable road users, operation at poor lighting conditions and eliminating false alarms without radar ambiguities.



To be clear, Arbe&rsquo;s financial performances have not been up to snuff. Last year, it could not mitigate expected losses per share. In the past four quarters, the average negative surprise came out to 15.43%. However, there could be improvement soon.



In fiscal 2024, experts believe Arbe will post a loss of 72 cents per share on revenue of $1.65 million. In fiscal 2023, the company delivered a loss of 71 cents on sales of $1.47 million. Even better, Arbe could potentially ring up sales of $31.35 million in fiscal 2025.



Analysts rate ARBE a <a href="https://www.tipranks.com/stocks/arbe/forecast">unanimous strong buy</a> with a $3 price target, implying over 36% upside potential. It&rsquo;s one of the penny stocks to keep on your radar.



<h2>KORU Medical Systems (KRMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/penny-stocks-300x169.png" alt="Stacks of pennies representing penny stocks. Nano-Cap Penny Stocks"><div>Source: John Brueske / Shutterstock.com</div></div>Operating under the medical instruments and supplies subsegment of the healthcare industry, KORU Medical Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/krmd-stock-quote/">KRMD</a>) offers what it terms freedom infusion systems. This solution delivers life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and <a href="https://www.korumedical.com/therapeutic-areas/pnh">paroxysmal nocturnal hemoglobinuria</a>. Since the start of the year, KRMD stock has gained over 5%.



In the past 52 weeks, shares swung up almost 15%, demonstrating solid near-term momentum. What&rsquo;s particularly interesting is that Koru has delivered some solid quarterly results. Aside from a bad miss in Q4, Koru has either met the expected loss per share or has favorably undercut the red ink.



For fiscal 2024, experts believe that the medical devices firm will post a loss of 14 cents per share on revenue of $31.69 million. Last year, the company incurred a loss of 30 cents on sales of $28.52 million.



Analysts peg KRMD a <a href="https://www.tipranks.com/stocks/krmd/forecast">unanimous strong buy</a> with a $3.38 price target, projecting almost 49% upside. It may be one of the more reasonable penny stocks to consider.



<h2>PowerFleet (PWFL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/penny-stocks-1600-300x169.jpg" alt="A concept image of a penny sitting on a stock chart"><div>Source: Billion Photos / Shutterstock.com</div></div>Falling under the communication equipment category of the technology ecosystem, PowerFleet (NASDAQ:<a href="https://investorplace.com/stock-quotes/pwfl-stock-quote/">PWFL</a>) provides wireless Internet-of-Things (IoT) asset management solutions in the U.S., Israel, and internationally. Per its <a href="https://finance.yahoo.com/quote/pwfl/profile">corporate profile</a>, the company offers real-time intelligence for organizations to capture IoT data from various types of assets with devices and sensors to increase efficiencies. It also provides many other services that help improve safety and security.



Since the start of the year, PWFL has already gained almost 51%. Therefore, it&rsquo;s one of the penny stocks where you&rsquo;ll be hoping strength begets even more strength. What&rsquo;s appealing here is PowerFleet&rsquo;s ability to pleasantly surprise. To be sure, it generally expands the expected red ink. However, in the first quarter of last year, the company posted earnings per share of 8 cents against a projected loss of 6 cents.



For fiscal 2024, experts believe EPS will land at 2 cents on revenue of $253.35 million. That&rsquo;s a dramatic improvement over a loss of 29 cents per share on sales of $133.59 million.



Analysts rate a <a href="https://www.tipranks.com/stocks/pwfl/forecast">unanimous strong buy</a> with an $8 target, implying 62% upside.



<h2>CarParts.com (PRTS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-fingers-300x169.jpg" alt="Image of a penny held between two fingers with a white indoor background. Dividend-Paying Penny Stocks"><div>Source: Shutterstock</div></div>Falling under the Internet retail category, CarParts.com (NASDAQ:<a href="https://investorplace.com/stock-quotes/prts-stock-quote/">PRTS</a>) offers a self-explanatory service. It operates as an online provider of aftermarket auto parts and accessories. Its main market is the U.S. and the firm also covers the Philippines. Fundamentally, the enterprise may benefit cynically from the challenges facing the consumer economy. People aren&rsquo;t rushing to buy new (or new-to-them) vehicles so they must keep their rides running well.



In theory, this dynamic should help PRTS swing higher as one of the compelling penny stocks. However, the market feels differently. Since the start of the year, shares have plunged more than 49%. In the past 52 weeks, they&rsquo;re underwater to the tune of 67%. I&rsquo;ll be straight up: this has been a falling-knife &ldquo;investment.&rdquo;



However, after a bum note in Q2, CarParts.com is showing signs of modest improvement. For fiscal 2024, analysts believe that it will roughly duplicate last year&rsquo;s revenue of $675.73 million. However, in 2025, the top line could rise to $697.55 million.



Covering experts peg PRTS a <a href="https://www.tipranks.com/stocks/prts/forecast">unanimous strong buy</a> with a $3.69 price target, implying almost 124% upside. It&rsquo;s something to think about.



<h2>Lantronix (LTRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-man-figurine-300x169.jpg" alt="penny stocks. Penny Stocks with Potential"><div>Source: Shutterstock</div></div>Operating under the communication equipment subcategory, Lantronix (NASDAQ:<a href="https://investorplace.com/stock-quotes/ltrx-stock-quote/">LTRX</a>) provides solutions for video surveillance, infotainment systems and intelligent substations infrastructure in the Americas, Europe, the Middle East, Africa and Asia-Pacific/Japan. From its <a href="https://finance.yahoo.com/quote/ltrx/profile">public profile</a>, Lantronix offers myriad solutions, including secure network connectivity, audio/video aggregation, computer vision and machine learning, among many others.



While one of the more relevant penny stocks, LTRX is incredibly volatile. Since the beginning of this year, shares stumbled 39%. Over the past 52 weeks, they&rsquo;re down more than 13%. However, recent sessions show a possible support baseline forming. Financially, it performs surprisingly well. In the past four quarters, the average positive earnings surprise came out to just under 30%.



For fiscal 2024, experts believe EPS will come in at 40 cents on revenue of $160.3 million. Last year, Lantronix posted per-share profits of 23 cents on sales of $131.19 million.



Again, analysts rate LTRX a <a href="https://www.tipranks.com/stocks/ltrx/forecast">unanimous strong buy</a> with a price target of $8.25. That implies 131% growth potential.



<h2>Adicet Bio (ACET)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-single-300x169.jpg" alt="A close up photo of a penny. Penny Stocks to Buy"><div>Source: Shutterstock</div></div>Plying its trade in the biotechnology sphere, Adicet Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/acet-stock-quote/">ACET</a>) focuses on the discovery and development of <a href="https://www.adicetbio.com">allogeneic gamma delta T-cell therapies</a> for autoimmune diseases and cancer. The company offers gamma delta T-cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, which targets autoimmune diseases and relapsed or refractory aggressive B-cell non-Hodgkin&rsquo;s lymphoma.



Over the past 52 weeks, ACET stock lost almost 58% of equity value. That sounds bad and it is bad. However, in the past six months, it&rsquo;s up 64%. Technically, something bullish appears to be brewing, which has excited the bulls. Notably, after expanding expected per-share losses, Adicet finally reached parity in Q4, delivering a loss of 69 cents.



For fiscal 2024, experts believe the company will post a loss of $1.86 per share. That would be an improvement over last year&rsquo;s loss of $3.31 per share.



Analysts rate shares a <a href="https://www.tipranks.com/stocks/acet/forecast">consensus strong buy</a> with a $9 target, projecting 286% upside potential. If the clinical trial gods favor Adicet, ACET could be one of the top penny stocks.



<h2>Vor Biopharma (VOR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-stack-chart-300x169.jpg" alt="a stack of pennies and a calculator lay stop a graph of market movements. Penny Stocks"><div>Source: Shutterstock</div></div>Another biotechnology specialist, Vor Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/vor-stock-quote/">VOR</a>) operates as a cell and genome engineering company. Its lead product is <a href="https://www.vorbio.com/platform-pipeline/our-pipeline/">tremtelectogene empogeditemcel </a>(trem-cel), an engineered hematopoietic stem cell that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. It&rsquo;s also developing other treatment candidates targeting various diseases.



As you might expect from penny stocks, VOR is incredibly volatile. Over the past 52 weeks, it lost nearly 60% of market value. However, in the past six months, it&rsquo;s up more than 4%. That may be a signal that the security is building a support baseline.



Financially, Vor is a pre-revenue enterprise so the optimism is linked to its clinical narrative. That said, in Q4, the company posted a loss per share of 39 cents, paring the expected loss of 50 cents. For 2024, experts believe it will lose $1.43 per share, an improvement over $1.75 per share in the red last year.



Finally, analysts rate VOR stock a <a href="https://www.tipranks.com/stocks/vor/forecast">unanimous strong buy</a> with a $14.25 price target. That implies almost 545% upside potential.



Penny Stocks



On Penny Stocks and Low-Volume Stocks:&nbsp;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&nbsp;<a href="http://investorplace.com/">InvestorPlace.com</a>&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&nbsp;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/the-penny-stock-a-list-7-high-profile-companies-on-the-verge-of-greatness/">The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genelux Corp. (GNLX – Research Report), Adicet Bio (...

Analysts Offer Insights on Healthcare Companies: Genelux Corp. (GNLX), Adicet Bio (ACET) and Entera Bio (ENTX)

The latest update is out from Adicet Bio (ACET). Adicet Bio, Inc. has unveiled promising preclinical data for its innovative cancer therapy candida...

Adicet Bio Showcases Promising ADI-270 Cancer Therapy Data

ANNX

ARBE

BGFV

ENTX

GNLX

HNST

KRMD

LTRX

NCMI

PRTS

PWFL

SGMT

Press Releases

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Opinion

Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Adicet Bio Stock (NASDAQ:ACET), Short Interest Report

People Also Watch